Previous recipients of the EURORDIS Black Pearl Awards 2012-2019
2019

**EURORDIS Members Award** – ALS Liga Belgium

**Volunteer Award** – Richard West

**Volunteer Award** – Russell Wheeler

**Young Patient Advocate Award** - Laëtitia Ouillade

**European Rare Disease Leadership Award** - Prof. Till Voigtländer

**Policy Maker Award** - Dr Edmund Jessop

**Visual & Audio Media Award** - Anne-Dauphine Julliand: Et Les Mistrals Gagnants

**Written Media Award** - Bojana Mirosavljević: Word for Life

**Scientific Award** - Prof. Philip Van Damme

**Company Award for Innovation** - Chiesi

**Company Award for Patient Engagement** - The HERCULES Project (Pfizer Inc, PTC Therapeutics, Roche, Sarepta Therapeutics, Solid Biosciences, Summit Therapeutics, Wave Life Sciences and Duchenne UK)

**Company Award for Health Technology** – Air Liquide Medicql Systems

**Lifetime Achievement Award** - Michael Griffith

2018

**Patient Organisation Award** – PHA Europe

**Volunteer Award** – Helene and Mikk Cederroth

**Volunteer Award** – Chris Sotirelis

**Young Patient Advocate Award** – Sammy Basso

**European Rare Disease Leadership Award** – Bruno Sepodes

**Policy Maker Award** – Elena Gentile

**Visual & Audio Media Award** – Special Books by Special Kids

**Written Media Award** – Serge Braun

**Scientific Award** – Prof Michele De Luca & Dr Thomas Hirsch

**Company Award for Innovation** – Novartis

**Company Award for Patient Engagement** – EFPIA, MSD, Bayer, UCB

**Lifetime Achievement Award** – Alastair Kent
2017

*Patient Organisation Award* – Dravet

*Volunteer Award* – Elizabeth Vroom

*Policy Maker Award* – Frédérique Ries

*Scientific Award* – Lucia Monaco

*Media Award* – Aldo Soligno

*Company Award* – GlaxoSmithKline

*Lifetime Achievement Award* – Anders Olauson

2016

*Patient Organisation Award* – UNIQUE – The Rare Chromosome Disorder Support Group

*Volunteer Award* – Tsveta Schyns-Liharska European Rare Disease

*Leadership Award* – Antoni Montserrat Moliner, Jarek Waligóra, Michael Hübel

*Policy Maker Award* – Christian-Silviu Bușoi

*Scientific Award* – Prof. Dr. Peter N. Robinson

*Media Award* – France Télévisions – AFM-Téléthon, France

*Company Award* – Actelion, Switzerland

*Lifetime Achievement Award* – Renza Barbon Galuppi, Italy

2015

*Patient Organisation Award* – Children with SMA

*Volunteer Award* – Rosa Sánchez de Vega European Rare Disease

*Leadership Award* – Prof Josep Torrent-Farnell

*Policy Maker Award* – Glenis Willmott

*Scientific Award* – Prof Kate Bushby

*Media Award* – Peter O’Donnell

*Company Award* – Pfizer, Inc.

*Lifetime Achievement Award* – Abbey Meyers
2014

**Patient Organisation Award** – Allianz Chronischer Seltener Erkrankungen

**Volunteer Award** – Lise Murphy European Rare Disease

**Leadership Award** – Paola Testori Coggi, Prof Guido Rasi, Prof Luca Pani

**Policy Maker Award** – Antonyia Parvanova

**Scientific Award** – Professor Hans-Hilger Ropers

**Media Award** – Rick Guidotti Company Award – Sobi

**Company Award** – Orphan Europe

2013

**Patient Organisation Award** – Alström Syndrome UK

**Volunteer Award** – Lesley Greene

**European Rare Disease Leadership Award** – Dr Ruxandra Draghia-Akli

**Policy Maker Award** – Françoise Grossetête

**Scientific Award** – Dr Ségolène Aymé

**Media Award** – Andrew Jack

**Company Award** – Celgene Corporation

**Company Award** – Proensa

**Company Award** – Genzyme, a Sanofi Company

2012

**Patient Organisation Award** - Association Française des Myopathies

**Volunteer Award** - Michele Lipucci Di Paola

**European Rare Disease Achievement Award** - Kerstin Westermark

**Policy Maker Award** – Andrea Vassiliou

**Scientific Award** - Professor Alain Fisher and

**Media Award** – BBC

**Company Award** – CSL Behring

**Company Award** – Shire

**Company Award** – Sigma Tau Pharmaceuticals, Inc
EURORDIS Volunteer Award – Richard West, Behçet’s Syndrome Society (UK)

For his admirable commitment of over 20 years as a dedicated advocate of rare disease issues on behalf of the Behçet’s community and his longstanding supportive partnership with EURORDIS.

The award also recognises Richard’s role as moderator of the Rare Connect Behçet Community, the founder of the International Behçet Society, as well as his longstanding and supportive partnership with EURORDIS, particularly as one of our representatives at the Patient and Consumer Working Party at the European Medicines Agency. His active involvement as a member of both TAG and our DITA task force - in particular his actions on off-label use of medicines in rare diseases - whilst also advocating on behalf of Behçet’s Syndrome, is testament to Richard’s drive and dedication to improving the lives of people living with a rare disease.
EURORDIS Volunteer Award – Russell Wheeler, Leber’s Hereditary Optic Neuropathy (LHON) Society (UK)

For his exceptional work as a patient advocate for all rare eye conditions (through LHON Society and as a patient board member of ERN-EYE) and for all rare diseases in his work as one of EURORDIS’ longstanding volunteers.

In addition, his active involvement at ISPOR and participation in the PFMD project have demonstrated his dedication and support to the cause. EURORDIS truly appreciates his supportive partnership as a member of our DITA Task Force and ePAG Steering Committee, an alumni of our Summer School, an EUPATI fellow, and an expert at the EMA. His motivation to make a difference to the lives of people living with a rare disease is reflected in all of his activities, and Russell Wheeler is a truly deserving recipient of this Award.
EURORDIS Written Media Award -
Bojana Mirosavljević (Serbia)

For her specialised journal for rare diseases ‘Word for Life’, which has brought the needs of people living with a rare disease to the attention of a wider audience in Serbia and beyond.

The content of the journal and the message it portrays is informative, and brings together important aspects of the rare disease cause. This Award acknowledges how ‘Word for Life’ shares with its readers powerful and supportive patient stories, knowledge and experience from rare disease experts, updates on rare disease legislation, and rare disease news from all over the world. EURORDIS appreciates Word for Life’s important contribution to raising awareness about rare diseases amongst families, medical professionals, and other relevant institutions across the Balkans.
EURORDIS Members Award –
ALS Liga Belgium (Belgium)

For ALS Liga Belgium’s great work in providing services and support that have significantly enhanced the quality of life of people living with amyotrophic lateral sclerosis (ALS) across Belgium and Europe.

The organisation’s efforts to ensure the stimulation and financing of scientific research on ALS through the establishment of ‘A cure for ALS’ are exemplary. EURORDIS truly appreciates their dedication to providing expert care and direct patient support, offering therapies for both patients and families through their partnership with Middelpunt and defending the rights of people living with ALS. The launch of several international humanitarian projects following the example of ALS Liga Belgium is testament to their drive to raise awareness and to ALS Liga Belgium’s commitment to the rare disease community.
EURORDIS Policy Maker Award - Dr Edmund Jessop, NHS England (UK)

For his outstanding work and support of the rare disease community through his dedication to patient advocacy and tackling rare diseases as a public health issue. As public health lead of the National Commissioning Group and author of the reform on highly specialised care in the UK, his role was of huge value in protecting the rare disease services at a time of important reform within the establishment of NHS England. His approach on reform for these services has resulted in significant improvement for care for rare diseases in the UK, with significant life increase and improvement for the 71 services concerned.

The Award also acknowledges Dr Jessop’s active involvement at a European level, as representative of the UK at EUCERD and the Commission Expert Group on Rare Diseases, actively supporting EUROPLAN, and championing European Reference Networks in bringing his expertise from the UK. Dr Jessop’s ongoing commitment to visiting the Centres of Excellence of the 71 nationally highly specialised healthcare services is invaluable to maintain their focus on the needs of patients, and is further testament to his motivation to improve the lives of people living with a rare disease.
EURORDIS Rare Disease Leadership Award - Professor Till Voigtländer (Austria)

For his outstanding leadership and commitment to the rare disease community and the positive impact he has made on rare disease policy both in supporting national advocacy actions in Austria with Pro Rare Austria and on a European level as Co-Chair of the European Reference Networks Board of Member States.

This award acknowledges Prof. Voigtländer’s commitment to rare diseases at the Clinical Institute of Neurology in Vienna, within the Austrian Ministry for Health and in support of patients, notably with ProRaris. His efforts in organising congresses and events to mobilise and bring together the leaders of individual patient organizations, which lead to the foundation and constitution of Pro Rare Austria, are exemplary. We also appreciate his important role as a communicator for the rare disease cause through countless talks and presentations on the topic both in Austria and abroad. Professor Till Voigtländer has been a key figure in advancing the rare disease across Europe and EURORDIS believes him to be a truly deserving recipient of this award.
EURORDIS Scientific Award - **Prof. Philip Van Damme, University Hospital Leuven (Belgium)**

For his exceptional achievements in the field of amyotrophic lateral sclerosis (ALS) research as well as his outstanding support and care for ALS patients through his collaborative work with the patient organisation ALS Liga Belgium.

As a distinguished leader of an ALS research programme, also a prolific author of academic publications, and by sharing his expertise on ALS research on his such as World ALS Day, Prof. Van Damme has shown your motivation and commitment to the rare disease community, informing the general public and raising awareness of the needs of people living with a rare disease. We truly appreciate Prof. Van Damme’s collaborative work with ALS Liga Belgium and his contributions to creating awareness, setting up fundraising campaigns for research, and referring patients for optimal care and support. Such a strong partnership between a top neurologist and a local patient organisation needs to be highlighted within the international ALS community and beyond, serving as a model example of excellent collaboration practice for other diseases.
EURORDIS Visual & Audio Media Award - Anne-Dauphine Julliand (France)

For her inspiring documentary film ‘Et Les Mistral Gagnants’ which raises awareness by following the lives of five children each living with a different rare disease.

By documenting these stories, and allowing these children to speak for themselves, Anne-Dauphine Julliand has helped portray an unfiltered and genuine insight into what it means for each of these individuals to live with a rare disease. EURORDIS acknowledges the excellent media coverage of this documentary, having been broadcasted in Belgium, Japan, Spain, Germany and Lebanon, and Anne-Dauphine Julliand’s appearance in several TV shows to promote her work. The Award honours her important achievement of bringing the needs of people living with a rare disease to a wider audience, and finding an engaging way to reach an audience that may not already be part of the rare disease community.
Young Patient Advocate Award -
Laëtitia Ouillade (France)

For her exceptional advocacy work to raise awareness of the needs of people living with a rare disease among a wider audience.

From giving talks and testimonies in school to Laëtitia’s involvement with AFM-Telethon, she has truly helped to inform the general public and raise awareness about SMA. Laëtitia’s dedication is reflected further in her TV and radio appearances, which have been instrumental in bringing awareness of the needs of people living with a rare disease to a wider audience. Her support and participation at the EURORDIS Summer School and the ECRD Vienna 2018 is another reflection of Laëtitia’s commitment to the rare disease community and EURORDIS believes she is a truly deserving recipient of this Award.
2019

EURORDIS Lifetime Achievement Award - Michael Griffith (Ireland)

For his exceptional work and vast achievements as co-founder of Fighting Blindness, founder of Debra Ireland and the Medical Research Charities Group, IPPOSI and Rare Disease Ireland. He has been a central figure in making a true and lasting difference for people living with a rare disease through his collegiate approach to advancing and funding medical research and providing platforms that represent the patient voice and improve patient access.

Michael Griffith has been a key player in providing platforms that represent the patient voice, improve patient access and collaboration in research and in turn, influencing the development of patient-centred health policy thanks to his innovative work with both Rare Disease Ireland and IPPOSI. The ripple effect of his impact has been phenomenal, with his passion, drive and energy continuing to inspire others. Michael Griffith has been a leader and driver for change and he is a truly deserving recipient of the EURORDIS Lifetime Achievement Award.
Company Award for Innovation - Chiesi (Italy)

For Chiesi’s strong commitment to rare diseases and its support to policy development, as well as its strong pipeline for bringing to market a wide number of treatments, including products for extremely rare diseases.

This Award recognises Chiesi’s significant investment in Research and Development for rare diseases and its involvement at the European level in recent years. Chiesi’s longstanding, supportive relationship with EURORDIS is another reflection of this dedication, including its membership of ERTC since 2007 and its support to many of EURORDIS’ projects, including the Black Pearl Awards, the Membership Meeting and RareConnect. The Award also recognises the Company’s support to policy development, as well as its strong pipeline for bringing to market a wide number of treatments, including products for extremely rare diseases.
Company Award for Health Technology
- Air Liquide Medical Systems (France)

For Air Liquide's longstanding commitment to the development of life-changing respiratory devices and services, benefiting the lives of many people living with a rare disease at an international level.

EURORDIS truly appreciates the Company’s continuous innovation, providing technological solutions and essential medical equipment to improve the lives of patients in hospitals, clinics, and at home. The Award also recognise Air Liquide's collaborative work with healthcare professionals and international research centres of excellence in order to meet patients’ needs and promote advances within the healthcare environment.
Company Award for Patient Engagement -
The HERCULES Project (Pfizer Inc, PTC Therapeutics, Roche, Sarepta Therapeutics, Solid Biosciences, Summit Therapeutics, Wave Life Sciences and Duchenne UK)

For the collaborative effort of all the companies involved in the HERCULES Project, bringing together patient organisations and industry to support access to new treatments for Duchenne Muscular Dystrophy (DMD).

The Project provides a unique, international platform allowing patient organisations and industry alike to come together and address key issues, develop high-quality evidence to support the HTA process, and in turn enable more transparent and consistent reimbursement decisions for new DMD treatments. The Award also recognises how the HERCULES Project has set a model example and has the potential to encourage similar initiatives across other rare diseases.
Chris Sotirelis is a patient with beta thalassaemia major. He has been a tireless patient advocate for EURORDIS and the rare disease community at national and international level for many years. He was involved in the first ever thalassaemia clinical outcomes patient registry until 2001. His expertise includes the setting up of the National Haemoglobinopathies Register (NHR), and previously being the UK Thalassaemia Society representative on the NHR commissioning group. Since then he has been directly involved in the development of surveys to assess patient quality of life. More recently, he has been leading the creation of a PROM (patient reported outcome measure) aimed at being integrated within the NHR. Its aim is to elicit areas of inequity and on how patients experience the impact of their treatment. His earlier work within the Sickle Cell and Thalassaemia Screening Programme Steering Group Committee has allowed him to give a patient perspective and help develop the ethics underlying screening for a genetic condition like thalassaemia, as well as on issues of “informed consent” and “informed choice.” As one of the European Medicines Agency’s (EMA) experts, affiliated to EURORDIS, he has strived to increase engagement in patient-critical areas within the wider EMA regulatory framework, and has been consulted on many Health Technology Assessment (HTA) Parallel Scientific Advice sessions. He has been an invited speaker to many conferences and workshops on Access and Reimbursement and, notably, has presented the “Patient perspective on HTAs for Personalised Medicine” during the plenary session debate of the HTAi conference in Bilbao in 2012.

He is very engaged as the lead representative of his patient community in NICE Health Technology Assessments (Single and Multiple Appraisals) and in drafting national commissioning policies for standard specification of care and orphan medicinal products for thalassaemia patients.
The awardee of the Written Media Award 2018 is Serge Braun for his book, 'On peut changer le monde, en vendant des crêpes et des ballons Dr. Braun worked for over a decade on neuromuscular diseases, working in university research, then in the private sector, where he conducted a gene therapy program dedicated to Duchenne muscular dystrophy, which led to the first worldwide clinical trial of gene transfer for a myopathy. He went on to work in cancer immunotherapy and HIV, whilst being vice-president of Alsace BioValley and co-founder of Neurofit, a company specialized in neurosciences.

From 2005, he joined the Association française contre les myopathies (AFM-Téléthon) and drove its scientific policy with one goal: the development of innovative therapies for rare diseases. The book for which he wins this award talks about both his experience as Scientific Director of the AFM-Téléthon as well as the cause of rare diseases and new developments in genetics, biology, and orphan drugs to cure these diseases.

Not only does the book didactically address scientific issues, it is through individual stories and anecdotes that Serge describes how the community has transformed the landscape of genetics, biology and orphan drugs. Through the testimony of families, researchers, doctors and volunteers, Serge gradually reveals the vision of ordinary people doing extraordinary things. Aimed at non-scientists as well as specialists, the book is both accessible and engaging, with profits going to the AFM-Téléthon.
Pulmonary Hypertension Association Europe is dedicated to improving the lives of patients living with pulmonary hypertension (PH) in Europe by working with its members to enhance awareness of PH, promoting optimal standards of care for people living with the disease, ensuring the availability of all approved treatments and encouraging research for new medicines and therapies. Founded in Vienna in 2003, the organisation has grown to a level where it now includes 29 patient associations from 33 countries in Europe. Their call to action, which was presented in the European Parliament in 2012, is to improve access to expert care, improve awareness and screening, encourage clinical research and innovation, empower patient groups and ensure the availability of psychosocial support. The European Parliament event on Organ Donation and Transplant in October 2016, initiated by PHA Europe, is an example of how far the organisation has succeeded in reaching out to the decision makers at EU level, thanks to close collaboration with the European patient federations for diseases where organ transplants are relevant. Four representatives from PHA Europe are also members of the ePAG (European Patient Advocacy Group) network.

PHA Europe recently conducted their ‘white spots’ programme. PHA identified countries in which there are no PH patient associations – ‘white spots’ – and consequently, in European countries with more than one million citizens, only two countries remain with no patient associations. PHA continued to grow with their fellowship programme, which aims to improve communication between member associations. The Annual PH European Conference (APHEC) gives member associations opportunities for capacity building as well as for information and education. The 2016 APHEC featured three international PH medical opinion leaders as speakers, a cardiologist, a pulmonologist and a paediatrician, who provided the attendees with the latest information on treatment strategies, surgery and research.
EURORDIS Policy Maker Award - Elena Gentile

Elena Gentile is an Italian politician who has supported the rare disease cause since she began practising as a paediatrician in Italy and throughout her political mandate. After gaining a degree in medicine and working as a paediatrician in Cerignola Hospital, Elena Gentile began her political career and, from 1985, she spent five years as Councillor for Health, Environment and Social Services in Cerignola, Italy and was elected Mayor of the city in 1991. As a respected political figure, she has used her position as a Member of the European Parliament since 2014 to help give a voice to Idiopathic pulmonary fibrosis (IPF) patient groups by supporting the first European IPF Patient Charter in EU Parliament and by mobilising MEPs around a written declaration on IPF. She has demonstrated her determination to collaborate with member states to enable access to EMA approved orphan products for IPF patients. Elena Gentile further exhibited her dedication to the improvement of rare disease policy through her support of the Parliamentary Advocates for Rare Diseases, a EURORDIS initiative which launched in October 2017. Her ongoing collaboration with UNIAMO, the Italian National Alliance for Rare Diseases, has resulted in the organisation of the photographic exhibition ‘Rare Lives’ at the European Parliament; and she is supporting the high level meeting on the European Reference Networks (ERNs) organised by the Rare Bone Diseases Network (ERN BOND) at the European Parliament on the occasion of Rare Disease Day 2018.
The Rare Disease Leadership Award 2018 is being deservedly presented to Professor Bruno Sepodes, an exceptional leader with international influence. Currently Professor of Pharmacology and Pharmacotherapy at the Faculty of Pharmacy of the University of Lisbon, he develops his research in Pharmacology and Translational Medicine. Simultaneously, he is completing his final year as Chair of the Committee for Orphan Medicinal Products (COMP), and is a member of the Committee for Human Medicinal Products (CHMP) and of the Committee for Advanced Therapies (CAT) at the European Medicines Agency. His collaboration with the European Medicines Agency started as a member of the COMP in 2008 and followed as a member of the Patients’ and Consumers Working Party during 2012. Bruno has exhibited his expertise further as an expert for the National Medicines Authority (INFARMED) and for the Veterinary General Directorate (DGV). Concerning the involvement in research projects, international collaborations include the William Harvey Research Institute (UK) and other relevant research institutes. A true leader in his field, Bruno has authored and co-authored over 70 scientific publications in international journals, and more than 100 scientific communications (on pharmacology, toxicology and therapeutics), presented to national and international scientific meetings. The EURORDIS European Rare Disease Leadership Award recognises Bruno’s long-standing collaboration with the European Medicines Agency and indeed EURORDIS as well as his outstanding leadership and commitment to the importance of including patient advocates as equal stakeholders in all discussions and decisions.
The recipients of the EURORDIS Scientific Award 2018 are Professor Michele De Luca and Doctor Tobias Hirsch, as well as their respective teams at the Centre for Regenerative Medicine “Stefano Ferrari” (CMR) at the University of Modena and Reggio Emilia (Italy) and the Severe Burn Injury Centre of the University Hospital of the Ruhr University, in Bochum (Germany) for their collaboration in developing a life-changing gene therapy. This therapy, which enables the human epidermis to regenerate through the use of transgenic stem cells, recently saved the life of a young boy named Hassan, affected by the rare disease junctional epidermolysis bullosa (EB). There are many forms of EB, most of which result in blistering and lesions of the skin and mucosal membranes. Due to the lack of available treatments, this disease significantly reduces the patient’s quality of life and can also be life-threatening.

After trying established therapies without success, Dr Tobias Hirsch’s medical team from Bochum, Germany decided to adopt an experimental approach. They took a sample of Hassan’s skin which was unaffected by the bacterial infection and sent it to Modena, where Prof De Luca’s team cultured in the lab a large amount of transgenic epidermis. This new skin derived from genetically modified stem cells was then transplanted onto the wound surfaces. Hassan is the first patient worldwide to have been treated successfully in the entire body by this gene therapy that was developed after many years of research by Prof Michele de Luca and his team, an exemplary example of cross-border scientific collaboration. Phase I/II clinical trials are now being carried out also on other types of epidermolysis bullosa. In the future it could be extended to treating other genetic skin conditions. Professor Michele De Luca is the Director, co-Founder and Scientific Director of Holostem Terapie Avanzate S.r.l. and the author of over 120 peer-reviewed publications. Through these ventures, he has exhibited his dedication to innovation in healthcare. In 2017, he was awarded The Niche’s Stem Cell Person of the Year Award. In 2014, Michele was one of the winners of the ISSCR Public Service Award for his involvement in public debate and policymaking in Italy and their championing of rigorous scientific and medical standards and stringent regulatory oversight in the introduction of new stem cell treatments into the clinic.

Prof De Luca and Prof. Graziella Pellegrini at CRM are also leading other innovative stem cell and regenerative medicine work including the development of Europe’s first stem cell-based ATMP (Advanced Therapy Medicinal Product), in the form of a new adult stem cell-based therapy for vision loss called Holoclar®.

Doctor Tobias Hirsch’s scientific career includes a past as a resident in Plastic Surgery at the University of Heidelberg. Between 2007 and 2010, he was a Postdoctoral Research Fellow at the Laboratory of Molecular Oncology and Wound Healing, at the BG University Hospital Bergmannsheil, Ruhr University Bochum, Germany. Additionally, between 2005 and 2007 he was a Postdoctoral Research Fellow and Member of Faculty in the Division of Plastic Surgery, at the Harvard Medical School, Boston, MA, USA.
The recipient of the Visual & Audio Media Award 2018 is Christopher Ulmer, who, founded Special Books by Special Kids, a video project that seeks to normalise the diversity of the human condition. After achieving a BA in Communications and a Masters Degree in Teaching, Christopher Ulmer became a teacher for children with disabilities ranging from brain disorders to autism, and was touched by the connection that he made with these incredible children who wanted to be understood in the world. He decided to create a book series where his students explained life from their perspective. Originally denied by 50 publishers, Christopher turned to Facebook as a tool to publish his interviews via video and, after 6 months, the page had over 150,000 followers. Spurred on by the support of the rare disease community, Christopher began to interview patients outside of the classroom, and soon decided to do his video interviews full-time in the hope of bridging the gap between individuals with a diagnosis and the general public.

Since the creation of Special Books by Special Kids, the Facebook page has 1.6 million likes, as well as 200,000 Youtube subscribers and 245,000 Instagram followers. By connecting societies around the world, he has helped build a global dialogue around rare diseases and has built a media movement that supports acceptance regardless of diagnosis. This award recognizes how Christopher has helped to portray an unfiltered and genuine insight into what it means for individuals to live with a rare disease, and how he has, importantly, found an engaging way to reach those not directly part of the rare disease community.
The EURORDIS Company Award for Patient Engagement recognises the achievements of the European Federation of Pharmaceutical Industries and Associations, Bayer, UCB and MSD, in particular recognising their leadership as a group in championing the development of patient engagement activities within the Innovative Medicines Initiative, particularly through the PARADIGM project...

It is timely to provide a framework that allows structured, meaningful, sustainable and ethical patient engagement throughout the development of medicinal products. In the longer term, this framework will strengthen both the understanding of stakeholders and system-readiness towards patient engagement across the diverse range of stakeholders, and ensure synergies with other initiatives focusing on the patient’s voice in the life cycle of medicines.

The development of an inventive and workable sustainability roadmap to optimise patient engagement across medicines’ R&D, demonstrates the inherent link between patient education, patient engagement and truly valuable innovation.

This Award celebrates commitment to meaningful engagement of patient representatives throughout the lifecycle of medicines.
Sammy Basso, who was born in Schio, Italy in 1995, is a patient advocate dedicated to raising awareness about Hutchinson-Gilford progeria. Sammy is the eldest of approximately one hundred people in the world living with progeria, and currently studies natural sciences, focusing on biology. Whilst only 9 years old, he helped to create his own advocacy group, l'Associazione Italiana Progeria Sammy Basso, which has been instrumental in informing the general public and promoting the need for progeria research.

Together with Bologna’s Institute for Molecular Genetics – National Research Council (IGM-CNR), l’Associazione Italiana Progeria Sammy Basso created the Italian Network for Laminopathies, a group of Clinical and Research Centers performing clinical and molecular diagnosis or biomedical research in the field of laminopathies.

As the driving force behind his advocacy group, he has been unstoppable in fulfilling his dreams to explore the world despite the apparent limitations of his condition, shown in his Nat Geo People Documentary, Il viaggio di Sammy, which documented his trip to the USA along Route 66, and his book of the same name.

Sammy plans to become a researcher and contribute actively to the study of progeria, for which he has already been instrumental in raising awareness.
The EURORDIS Company Award for Innovation recognises Novartis for its longstanding track record in developing medicines for rare diseases. Through effective collaborations with the scientific, medical and patient communities, Novartis has a promising pipeline to address many rare diseases, including rare cancers. In 2017, Novartis received the first FDA approval for a gene therapy to treat cancer in children and young adults.

EURORDIS applauds the innovation that is the hallmark of the rare disease community. There are over 6000 rare diseases, an estimated 30 million people living with a rare disease in Europe and 300 million worldwide. The fact remains that few treatments are available for the majority of these diseases; many have no appropriate treatment or go undiagnosed. Continued innovation through effective collaboration is needed now for the millions of people worldwide who are living with a rare disease, for which Novartis is an excellent example.
Alastair Kent is an expert in his field who has changed the face of genetic research in his long and dedicated career, providing patient support for children, adults and more families living with different forms of genetic disorders.

A central figure in the UK, Europe and worldwide, he has influenced and advised patient organisations, the charitable sector and indeed government through the Department of Health. Campaigns led by Alastair have significantly influenced legislation to the benefit of patients and have received the gratitude of lawmakers. Since 2013 Alastair has sat on the NHS England Rare Diseases Advisory Group, the Genomics England Ethics Advisory Committee, the Scottish Medicines Consortium Task & Finish Group on Improving Access to Medicines for Patients with Rare Diseases and the Department of Health’s Rare Diseases stakeholder forum, which he has chaired from 2014. Since 2004 he has sat on the Public Population Projects in Genetics (P3G) Ethics Committee and the UK Genetics Testing Network Steering Committee for the Department of Health since 2003. He has also sat on: the Royal College of Physicians (Now Joint Committee of the Royal College of Physicians, RCPath and British Society for Human Genetics) Clinical Genetics Committee (since 1997); the Association of British Insurers Genetics Advisory Committee (since 1996); and the European Alliance of Genetic Support Groups (since 1993) of which he became president in 1995.

Prior to becoming the director of Genetic Alliance UK, Alastair was director of Action for Blind People between 1989 and 1993, as well as being Director of Education, Employment and Residential Services at the Royal National Institute for Deaf People between 1986 and 1989. From 1982 until 1986 he was Principal of Barnstead Place at Queen Elizabeth’s Foundation for the Disabled, before which he worked as a County Careers Officer specialising in special needs for North Yorkshire County Council between 1981-82. From 1977-1981 he was a Specialist Careers Officer for Cambridge County Council and before this was a careers officer for Norfolk County Council from 1973 until 1977. From 2007-2013 Kent was a member of the ethics committee for the ‘1000 Genomes’ International Project. Between 2008 and 2011 he was on the EMEA committee for advanced therapies. He has been recognised by his country for his numerous services to healthcare with an OBE, and thus we hope that this Lifetime Achievement Award from EURORDIS is a fitting recognition from fellow representatives and practitioners of the rare disease community.
Elizabeth Vroom is mother to a son with Duchenne Muscular Dystrophy (DMD) and founded the Duchenne Parent Project in the Netherlands, of which she remains president to this day. In 2002, Elizabeth co-founded the United Parent Projects Muscular Dystrophy (UPPMD) through which she helped establish World Duchenne Awareness Day. “Receiving an award is very special, but even more so because this comes from a community I treasure and consider as family. I am very honoured to receive the Volontéer Award for 2017 as I know how many people like me work hard to change the lives and future of patients with rare diseases.” – Elizabeth Vroom

**EURORDIS Volunteer Award – Elizabeth Vroom**

Lucia Monaco is Chief Scientific Officer at the Fondazione Telethon and has made a significant impact in the field of rare disease in Italy and abroad, in particular through her strong commitment to the IRDiRC initiative. Her personal enthusiasm, guidance and dedication inspires many scientists and clinicians to become involved in state-of-the-art research for rare diseases such as the development of gene therapies. “I feel deeply honoured receiving this award, which I believe really recognizes the value of the organization which I have the fortune to work with, as well as the value and the extraordinary results of our scientists. The Fondazione Telethon is a charity which is committed to fight rare genetic diseases and to do this we support excellent research, but our mission is to bring the results of this research to patients. The results we have seen over the past few years could not have been achieved without a strong collaboration among all of the stakeholders, colleagues, patients and their families.” – Lucia Monaco

**Scientific Award – Lucia Monaco**

Anders Olauson has devoted the past 30 years of his life to the rare disease cause. In 1989 he founded the Ågrenska Centre, a national competence centre in Sweden which provides support for people affected by rare diseases. President of the European Patients’ Forum from 2005 to 2015, Anders remains Honorary President of the organization. “I think it’s fantastic that I just want to share it with so many people to have this award. It’s a recognition that all the work you have done, all the travels and all the things and energy you have put in, that it has given a result and that result has been so greatly appreciated. I am totally honoured. Having a rare disease affects all aspects of life; experiences from thousands of families worldwide tell the same story. All areas of life – healthcare, social services, schools, insurances and labour – must work together. Life is holistic, as should care and support be. Working together at the United Nations will make this possible.”

**Lifetime Achievement Award – Anders Olauson**

In October 2014, Aldo Soligno led the project ‘Rare Lives’, a powerful photographic storytelling tool that gives an insight into the daily lives of people living with a rare disease. “Spending days and weeks with families and patients suffering from a rare disease has meant so much to me to see how opposites can meet and turn into one another: weakness into strength, sadness into joy, despair into determination. Seeing this happen simultaneously in 7 different European countries has confirmed to me that there are no boundaries for scientific research and solidarity and they must not exist for rare disease patients too. I really hope this will be the legacy of my project.” – Aldo Soligno

**Media Award – Aldo Soligno**
Policy Maker Award – Frédérique Ries

Frédérique Ries, Member of the European Parliament since 1999, has been a pioneer in the implementation of patient-centric health policies that focus on Unionadded value, especially in the field of rare diseases. Her most recent work, a project proposal that promotes a continuous bottom-up research approach including patients, demonstrates Ries’ consistent dedication towards tackling rare diseases in the European Union.

Patient Organisation Award – Dravet

The Dravet Syndrome European Federation was founded in 2014 by eight patient organisations in seven countries. They now work together to raise awareness and to fight the impact of Dravet Syndrome—also known as Severe Myoclonic Epilepsy of Infancy (SMEI)—on patients and their families. “It is extremely important to us to receive this recognition. Personally for me EURORDIS is like my family. I attended the summer school 3-4 years ago and I have learnt so much from all that EURORDIS is doing. We are a new federation that has developed over the past 3 years. We created this federation with the determination of working on new treatments for Dravet, working in three pillars: Removing the barriers for research such as developing a new animal model to help facilitate treatment and how new drugs can be tested for Dravet. Digital transformation for our patients and preparing important and the right data for our clinicians, researchers, physicians and patients. And lastly collaboration between different multi-stakeholder groups. These are the 3 pillars in which we base our work.” Julian Isla

Company Award – GlaxoSmithKline

Since 2010, GSK has designated rare diseases as one of its core therapeutic areas. In 2016, GSK brought to market an innovative gene therapy to treat patients with the rare disease adenosine deaminase severe combined immunodeficiency syndrome (ADASCID). “It is a huge privilege and a great honour, as well as humbling to accept this award on behalf of GSK. Since coming into the rare disease universe, I have felt overwhelmed by the welcome that you get, that everyone has a single-minded goal which is all around patient treatment and patient outcome. You don’t have to look very far to be inspired in this world. This award goes to all the people who have the courage, determination and focus, and who put in all their energy to make a change for all people living with severe rare disease. And of course to all the patients and families who drive us each day.” Martin Andrews
Policy Maker Award – Christian-Silviu Bușoi

Cristian-Silviu Busoi, Member of the European Parliament since 2007, has consistently demonstrated a strong vision of patient-centric, quality and accessible medical systems across Europe in this position. A physician and former lecturer in Public Health and Health Management at the Victor Babes University of Medicine and Pharmacy. As a member of the ENVI Committee within the European Parliament, he has used this platform to champion patients' rights in each country, launching the public “Patients’ rights’ campaign, supporting a multi-centre collaboration at EU level to encourage partnerships between all rare disease stakeholders. In holding parliamentary events in support of rare cancers and rare diseases, and co-hosting the Rare Disease Day policy event to improve access to therapies for rare diseases, he has shown devotion passion in addressing the needs of rare disease patients across Europe, making him a truly deserving winner of the EURORDIS Policy Maker Award 2016.

Volunteer Award – Tsveta Schyns-Liharska

Tsveta Schyns-Liharska has a Phd and Post doc in genetics from Wageningen University and the Free University in Amsterdam, respectively. As a parent of a daughter affected with the rare disease alternating hemiplegia, Tsveta has dedicated a considerable amount of time to caring for her daughter and to volunteering for the rare disease community. Tsveta’s volunteer activities include being a patient representative on the Paediatric Committee (PDCO) of the European Medicines Agency since 2008 and for 8 years dedicating a massive amount of time and work as Scientific Coordinator of the European Register for Multiple Sclerosis Project. A true achievement has been the founding and running, as Secretary General, of ENRAH and the work Tsveta has done for the EU Public Health Programme. This award serves to recognise all that Tsveta has accomplished in supporting so many rare disease organisations on a volunteer basis and to recognise her long and faithful service as a EURORDIS volunteer.

Chromosome Disorder Support Group Patient Organisation Award – UNIQUE – The Rare

UNIQUE has been a source of mutual support and self-help to families of children with a rare chromosome disorder since it was founded by Edna Knight MBE in the UK in 1984 as the Trisomy 9 Support Group. Starting with 1192 families, to now representing over 14,000 families world-wide in over 90 countries, UNIQUE as an organisation has worked hard to raise awareness of rare chromosome disorders to professionals and to the general public so that they too have an appreciation of the extraordinary challenges their members face. This incredibly well-deserved award serves to recognise the efforts and successes that have resulted from the hard work and determination of UNIQUE.
Scientific Award – Prof. Dr. Peter N. Robinson, Institute for Medical Genetics, Universitätsklinikum Charité, Germany

Support Group, U

Professor Peter N. Robinson is a Professor for Medical Genomics at the Charité Universitätsmedizin Berlin in Germany, as well as Research Group leader at the Institute of Medical Genetics and Human Genetics of the Charité – Universitätsmedizin Berlin. Amongst other activities, Peter has developed the Human Phenotype Ontology (HPO), as well as a number of algorithms for disease gene prediction and next-generation sequencing data. His developments contribute also to correlate animal models and human diseases. Peter’s team’s output in recent years has included the development of a novel treatment strategy for Marfan syndrome in mice based on antagonism of a class of bioactive motifs that are common in fragments of elastin and fibrillin-1, the identification of novel disease genes for a form of ataxia (CA8) and hyperphosphatasia with mental retardation syndrome (PIGV). Peter Robinson has concentrated his diverse background and skills to improve the understanding and the diagnosis of inherited disease.

Lifetime Achievement Award – Renza Barbon Galuppi, Italy

Renza Barbon Galuppi is believed to be a “wonder woman” for her ability and strength to be where she is needed at the right moment, even though it means attending conferences, meetings and workshops in three different cities in two days. It has been calculated that in the past few years she has spent an average of 15 hours a day in activities related to Rare Diseases advocacy and to answering individual patients or Patient Organisations and organizing projects to train Rare Disease patients’ representatives on key topics. It all started with the diagnosis of a typical type of hyperphenylalaninemia given to two of her three children. The delay in the delivery of the diagnosis to her eldest daughter and its consequences led her first to start the collaboration with the Patient Organisation involved in metabolic diseases but shortly after with UNIAMO, the Italian Federation of Rare Diseases, to contribute to addressing all the transversal needs. In the past 10 years, Renza has contributed to stressing the importance for patients with Rare Diseases to share their experiences within associations and promote their integration into the community in every facet of life. In particular, she has advocated for patient representatives to be part of the expertise and decision making process, and has committed to the social innovation project, ‘Ristoro Fantasia’, overcoming mental and social barriers within young patients affected by rare diseases.

Media Award – France Télévisions – AFM-Téléthon, France

The EURORDIS Media Award recognises the longstanding support of France Télévisions in broadcasting live the French Téléthon. Millions of people have taken part and donated to the AFM-Téléthon cause, making it possible to support research and create the Institute of Biotherapies for Rare Diseases, with laboratories such as the Myology Institute, Généthon, I-Stem et Atlantic Gene Therapies. Généthon, for example, stands out through its unique ability to develop, produce and test its own innovative gene-based medicines for rare diseases, the creation of which has been made possible from the proceeds of the AFM-Téléthon. Moreover, thanks to the French Téléthon, it has been possible to inform the general public about rare diseases, promote changes in the legal framework in France and in Europe and improve the daily life of patients.
Established in 1997, Actelion focuses on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. The Company has, in particular, made a difference for pulmonary arterial hypertension (PAH) in Europe and globally. Actelion’s pipeline reflects continued commitment to address unmet medical needs, and they have engaged with and supported patient organisations since their founding. An Emerald member of the EURORDIS Round Table of Companies (ERTC), Actelion has supported several key EURORDIS initiatives, including: the EurordisCare survey, EURORDIS Membership Meetings, and the Black Pearl Evening, which helps make possible EURORDIS’ actions to end isolation of people living with a rare disease, empower leaders of the rare disease patient community, and raise awareness of all rare diseases.

European Rare Disease Leadership Award – Antoni Montserrat Moliner, Jarek Waligóra, Michael Hübel

EURORDIS has decided to jointly present the European Leadership Award 2016 to three key pioneers from the Directorate General of Health and Food Safety (DG-SANTE) within the European Commission. Antoni Montserrat Moliner has championed patient engagement, particularly in his involvement in EUROPLAN and National Plans. Montserrat has driven encouraging actions in rare cancers, ensuring such patients can benefit from advances in both the cancer and rare disease fields. A clinical genetic paediatrician by training, Jarek Waligóra has tirelessly brought his medical expertise to his position of Policy Officer for rare diseases at the European Commission (EC). Waligóra specifically worked on the EC report on the implementation of the Council Recommendation on Rare Diseases, and has been pioneering in setting the policy agenda for the first and the current Rare Disease Joint Actions. Michael Hübel, Head of the Unit of Programme Management and Diseases at DGSANTE within the European Commission, has been instrumental in initiating and supporting policies around rare diseases, notably in the establishment of the Commission Expert Group on Rare Diseases and the Commission Expert Group on Cancer Control.
European Rare Disease Leadership Award –
Professor Josep Torrent-Farnell

Professor Josep Torrent-Farnell is a qualified Pharmacist and a specialist in Internal Medicine, and is a member of the Scientific Advice Working Party (SAWP) at EMA, Professor of Clinical Pharmacology and Therapeutics at the Autonomous University of Barcelona, and former Director General of the Fundació Doctor Robert, Advanced Centre of Services and Training for Health and Life Sciences. Josep has consistently demonstrated extraordinary leadership in the field of rare diseases, beginning with his membership of the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency in 2000 where he later went on to serve as First Chairperson for 6 years. He is also a member of the European Task Force for Rare Disease (DG SANCO). EURORDIS is delighted to present Professor Torrent-Farnell with the European Rare Disease Leadership Award as a symbol of his tireless devotion to, and his pioneering leadership of, the rare disease community.

Josep continues to be a long-standing supporter of EURORDIS and the projects we undertake such as the Summer School and the Round Table of Companies Workshops and participates in collaborations with over 70 patient organisations.

Policy Maker Award – Glenis Willmott

Glenis Willmott, Labour Member of the European Parliament for the East Midlands in the UK since 2006 and threetime re-elected leader of the European Parliamentary Labour Party, has demonstrated outstanding dedication and commitment in addressing the needs of patients in the European Union. Ms Willmott is an active member of various committees and forums such as the Environment, Public Health and Food Safety Committee, the Delegation for relations with Canada, and the MEPs against Cancer Forum. Yet most remarkable of all is the instrumental role Ms Willmott has played in the passing of key legislation through her work as Rapporteur for the “Regulation on Clinical Trials on medicinal products for human use” and Shadow Rapporteur for the Regulation establishing a “Health for Growth Programme”. These two pieces of EU legislation have a tremendous impact on the lives of the estimated 30 million people living with a rare disease in Europe.

Media Award – Peter O’Donnell

Peter O’Donnell is a prominent writer and editor in the rare disease field currently working as Associate Editor of the European Voice. His impressive career has spanned over twenty years and various countries and has included working for prestigious newspapers such as The Financial Times, The Sunday Times, Reuters, the Economist Intelligence Unit and United Press International. He has worked as an editor, editorial adviser and speechwriter for numerous clients in the corporate, political and academic world and has frequently chaired EU-level policy debates and lectures on EU affairs. This has made him very well placed to be able to write and report forthrightly on the various complicated and rapidly evolving issues surrounding rare diseases such as policy, at which he is incredibly skilled. In October 2013 he spoke at the Lunch Debate on Data Protection at the European Parliament. It is for these reasons that EURORDIS is delighted to award him this year’s Media Award.
Volunteer Award – Rosa Sánchez de Vega

As a rare disease patient herself, and the mother of a son of the same condition, Rosa Sánchez de Vega is a truly remarkable woman who has successfully managed to channel her difficulties and struggles with Aniridia into a positive force for change. She founded the Spanish Aniridia Association, for which she served as president until 2008. In 1999, she went on to co-found the Spanish Alliance for Rare Diseases (FEDER), serving first as Vice President and then President until 2010. Rosa joined the EURORDIS Board of Directors in 2003 and has served as Vice President from 2006 until 2013.

She has been recently appointed President of the European Federation of Aniridia, Aniridia-Europe. Ms Sánchez de Vega is an incredibly deserving recipient of the Volunteer Award as she has worked tirelessly and selflessly, often putting the rare disease cause beyond her own needs, in order to shine a light on rare diseases and improve the lives of others.

Patient Organisation Award – Children with SMA – Vitaliy Matyushenko

“Children with SMA” is a voluntary, non-profit foundation which has undertaken the incredibly difficult mission of supporting those affected by, or involved with, Spinal Muscular Atrophy (SMA) in Ukraine. Among genetic diseases, it is a leading cause of death among children under age two. For almost 10 years, Children with SMA has worked tirelessly on behalf of those who suffer from SMA, promoting knowledge around the disease and encouraging dialogue between legislators, doctors, researchers and patients. This incredibly well-deserved award serves to recognise the efforts and successes that have resulted from the hard work and determination of Children with SMA in Ukraine such as its contribution to the adoption of the law for Rare Diseases in Ukraine in April of this year and the foundation of the Ukrainian National Alliance.

Company Award – Pfizer, Inc.

Pfizer is one of the world’s premier pharmaceutical companies, and has demonstrated commitment to the rare disease cause - with 22 approved products to treat rare diseases worldwide including 4 in Europe. In 2010, Pfizer established its own Rare Disease Research Unit (RDRU), with the objective of taking an innovative and collaborative approach to the development of new medicines to create novel therapeutics across the spectrum of rare diseases. The current pipeline includes clinical and pre-clinical programmes in several rare diseases including sickle cell disease, haemophilia, muscular dystrophies, cystic fibrosis, and-more. Through this award, EURORDIS recognises the role major pharmaceutical companies can play in the development of, and ensuring access to, innovative treatments for rare disease patients. The award also encourages companies to maintain a high level of corporate social responsibility by reassessing the value of medicines today so as to ensure that unmet medical needs are covered in the development of new treatments.
Lifetime Achievement Award – Abbey Meyers

Abbey Meyers is an extraordinary woman: once a housewife and mother from Connecticut, USA, Meyers was drawn into the world of political advocacy, fundraising and organisation development when it became painfully apparent through her experience as the mother of a child with Tourette syndrome, that patients with rare diseases were being neglected in favour of more common diseases that affected larger patient populations. Meyers founded the National Organization for Rare Disorders (NORD) in the USA, organisation dedicated to helping people with rare diseases and to the identification, treatment and cure of rare diseases through education, advocacy, research and service. Indeed, NORD was the precursor and inspiration for the creation of EURORDIS. This Lifetime Achievement Award serves to honour all that Ms Meyers has done for the rare disease community in the USA and throughout the world, her personal and tireless dedication to the cause and her instrumental role in the passage of landmark policies such as the Orphan Drug Act of 1983, which has served as the model for rare disease legislation beyond the USA.

Scientific Award – Professor Kate Bushby

Professor Kate Bushby (MD FRCP) is a Professor of Neuromuscular Genetics and currently holds joint appointments between Newcastle University and the NHS. Her commitment to research in rare diseases, in particular inherited neuromuscular diseases, has been evidenced through her impressive publication list, clinical activities and involvement in policy actions. Prof Bushby is actively involved in many European projects including being a founding co-ordinator of the TREAT-NMD. Kate has played a leading role in the European and national rare disease policy area, acting as vice chair on the EUCERD from 2010 to 2013, which was mandated to assist the European Commission in the implementation of rare disease activities in all member states and she still acts in the capacity of invited expert on the new Commission Expert Group on Rare Diseases. In November 2014, Kate Bushby launched the John Walton Muscular Dystrophy Research Centre. The Centre will focus on three key research areas: translational research, innovative clinical trials and international networking. Kate has continuously demonstrated her true commitment to patients at many levels.
Policy Maker Award – **Antonyia Parvanova**

Dr Antonyia Parvanova, Member of the European Parliament since 2009, has shown an outstanding commitment to rare diseases: Dr Parvanova has since 2007 advocated for a ‘Europe for Patients’ emphasising the importance of improving access to medicinal products, and the benefits of cross-border healthcare: Such relentless advocacy activity has allowed this topic to rise in the European political agenda leading to the adoption of the Directive on the application of Patient’s Rights in Cross-border Healthcare. She worked as a paediatrician, expert and researcher in the field of healthcare management in the United Kingdom before launching her political career as an elected member of the Bulgarian Parliament in 2001 and then again in 2005. Alongside her persistent commitment to healthcare within the European Union; Dr Parvanova also strongly advocates for women’s rights and gender equality, and to remove visa regulations imposed by the US and Canada upon Eastern European Countries.

European Rare Disease Leadership Award – **Paola Testori Coggi**

Paola Testori Coggi, biologist by education, was nominated as Director General for Health and Consumer Protection at the European Commission in 2010. In this position, she has facilitated European cooperation in the field of rare diseases through several important steps. For instance, the approval of the rare disease priority within the Health for Growth Programme; the adoption of a fundamental piece of legislation to facilitate patient mobility through the Directive on Patients’ Rights in Cross-border Healthcare, crucial for rare diseases patients; as well as by taking the responsibility for the European Medicines Agency within her Directorate General.

European Rare Disease Leadership Award - **Professor Guido Rasi**

Professor Guido Rasi MD became Executive Director of the European Medicines Agency (EMA) in 2011 and has been pivotal in increasing the transparency of the agency’s work. He has encouraged more dialogue between patients, heads of scientific committees, and health technology assessment (HTA) bodies, and promotes access to clinical trial data. Professor Rasi’s overarching leadership and drive for collaboration between all rare disease stakeholders has undoubtedly facilitated the road to the authorisation of orphan products in Europe.
Professor Luca Pani MD, D.Psych undertook the role of Director General of the Italian Medicines’ Agency (AIFA) in 2011. In this position he has emphasised the importance and urgency in creating orphan medicinal products, ensuring investment into rare disease research and granting the access to sustainable and successful treatments for those living with a rare disease. As a leader, Professor Pani has used initiative and experience to drive the equal access to cures for rare diseases, not only in Italy, but in Europe as a whole.

ACHSE represents 120 rare disease patient organisations in Germany and has been instrumental in strengthening the voice of rare diseases and turning Germany into one of the most committed Member States in the European Union for rare diseases in the fields of research, information, healthcare, organisation and drug development. It has contributed to the progress NAMSE, which was presented to the German Health Minister in September 2013. The organisation is very active in raising awareness of rare diseases in Germany, having participated in Rare Disease Day since its launch in 2008, and by enlisting Eva Louise Köhler, the former First Lady of Germany, as an official patron of the organisation. ACHSE is exemplar of a valuable and effective platform for rare diseases, making them most deserving recipients of the EURORDIS Patient Organisation Award 2014.

A graduate of New York’s School of Visual Arts, Rick Guidotti led a successful career as a fashion photographer; every day he photographed what society deemed the most beautiful people in the world. This perspective was called into question after a chance encounter with a beautiful young girl living with the rare disease Albinism at a New York City bus stop. When he began to research the disease, he was troubled by the dehumanisation of people with rare diseases in medical textbooks. Since then, Rick Guidotti has launched a non-profit organisation, Positive Exposure, to change public perceptions of people living with genetic, physical and behavioural differences. The association runs educational and advocacy programs, organises exhibitions in public places and works with other NGOs and medical societies to give “positive exposure” to the beauty of those living with rare diseases. It is in the essence of his approach to changing the perception of beauty on a global scale for people with rare diseases that EURORDIS awards the EURORDIS Media Award 2014 to photographer Rick Guidotti.
Company Award – Sobi

Sobi, an international healthcare company dedicated to rare diseases, focuses on developing innovative treatments across four key therapeutic areas: haemophilia, inflammation/autoimmune diseases, inherited metabolic diseases and oncology. Sobi is particularly sensitive to the need for targeted treatments that are accessible to paediatric populations. Sobi’s track record of creating successful dialogue with patient communities demonstrates their objective for a transparent and progressive rare disease framework. Sobi is represented on several European Union committees such as the Commission Expert Group on Rare Diseases (replacing the EUCERD) and the working group on Mechanism of Coordinated Access to Orphan Medicinal Products (MOCAOMP). This award recognizes the excellence and consistency of Sobi’s work in the rare disease community.

Company Award – Orphan Europe

Orphan Europe, forming part of the Recordati group, has 25 years’ experience in bringing orphan medicinal products to the market. Seven orphan products produced by Orphan Europe have been authorised to date and this rich portfolio of successful treatments is supported by the robust pipeline of medicines in development. Orphan Europe’s support in the development of European Reference Networks EuroWilson, EPNET, E-IMD, E-HOD has helped to provide European guidelines for best care and treatment of rare disease patients. Strong alliances with patient organisations mark the central point of Orphan Europe’s platform for therapy development, working alongside patient organisations for cystinosis, renal genetic diseases (AiRG), metabolic diseases and porphyrias. Orphan Europe also consistently supports networking and capacity-building for rare disease patient advocates via the EURORDIS Membership Meeting.

Scientific Award – Professor Hans-Hilger Ropers

Hans-Hilger Ropers is Director at the Max-Planck-Institute for Molecular Genetics in Berlin and Professor of Human Genetics at the Humboldt University. Dr Ropers has made many contributions to the molecular elucidation of monogenic disorders by positional cloning; his department forms part of the European MRX Consortium, and more recently, he has implemented very high resolution array CGH for the high-resolution detection of small unbalanced rearrangements in large cohorts of patients with monogenic and complex disorders. In total, Dr Ropers has published over 300 research articles. Between 1985 and 1993, H.H. Ropers served as Chromosome Chair and Co-Chair at several Human Gene Mapping Conferences. He is a member of HUGO since the year of its inception as well as member of the HUGO Council and the Human Genetics Meeting Scientific Program Committee. It is in recognition of Dr Roper’s scientific excellence and untiring dedication to put single gene disorders into focus worldwide that we award Dr Hans-Hilger Ropers the EURORDIS Scientific Award 2014.
Volunteer Award – Lise Murphy

As an individual affected by the rare disease Marfan syndrome, Lise Murphy has had the experience this inherited disease across three generations, with her father and son also affected. In 2003, Lise Murphy was invited to be a member of the Board of Directors of the Swedish Marfan Organisation, (Svenska Marfanföreningen), and in 2004 became its Chairperson. Reaching beyond her own disease community, Lise Murphy has helped to catalyse the rare disease movement as a whole in Sweden, and for two years (between 2004 and 2006) she served on the board of the Swedish Rare Disease Alliance. Notably, from 2007 Lise Murphy represented EURORDIS at the European Medicines Agency’s Patient and Consumer’s Working Party (EMA-PCWP), and between 2010 and 2013 Lise Murphy held the responsibility of being co-chair of this working party. She has been instrumental in closing the gap between patients, health care professionals and pharmaceutical agencies, demonstrating the importance of patient dialogue and her unique brand of enthusiasm, energy and Swedish directness has added a special touch to all that she has done.

Lifetime Achievement Award – Marlene Haffner

For over 30 years, Dr Marlene Haffner has had an immeasurable impact upon the development of orphan drug therapies. Dr Haffner worked as the Director of the Office of Orphan Products Development at the United States of America Food and Drug Administration (FDA) for over twenty years, and she then applied her valuable knowledge and experience to assist the development of similar orphan drug programmes internationally. Dr Haffner’s role in the FDA placed her in a unique position, bridging the gap between patient support groups and regulated industry with the common objective to develop successful orphan products. During her time at the FDA, over 300 products were brought to the market. These 300 medicines gave around 15 million people living with rare diseases in the USA alone access to treatment. After stepping down from the FDA, Dr Haffner spent two years as Executive Director of Global Regulatory Intelligence and Policy within Amgen, the largest biotech company in the world. She then founded Haffner Associates, of which she is now President. In this role, Dr Haffner applies her unmatched knowledge of the rare disease political landscape to consult and work together with patient advocacy groups and pharmaceutical and biotech companies of all sizes. She trained as an internist and haematologist, and spent five years as Director of the Office of Health Affairs at the center of Devices and Radiological Health. Due to Dr Haffner’s admirable dedication within the field of Public Health, she rose to the rank of Rear Admiral in the United States Public Health Service (USPHS). The EURORDIS Lifetime Achievement Award is being awarded to Dr Marlene Haffner in recognition of her strong, lifetime dedication and commitment to addressing the needs of people with rare diseases.
Policy Maker Award – Françoise Grossetête

Ms Françoise Grossetête has been a Member of the European Parliament for almost 20 years. With her leadership as MEP and Rapporteur on several legislations, two essential EU Regulations have been adopted on Orphan Medicinal Products in 1999 and the Regulation on Medicines for Paediatric Use in 2006. Her interventions in favour of the EU Regulations on Advanced Therapy Medicinal Products and in the discussions around rare disease patients’ mobility within the negotiations on the Cross Border Healthcare Directive, have always been instrumental in achieving the best possible outcomes for rare diseases patients. As a Member of the Committee on Environment, Public Health and Food Safety and as a Substitute of the Committee on Industry, Research and Energy, she has supported several amendments boosting research and securing Public Health projects in areas directly or indirectly making an impact on the rare disease field.

European Rare Disease Leadership Award – Dr Ruxandra Draghia-Akli

Dr Draghia-Akli is Director of the Health Directorate at the Research & Innovation DG of the European Commission. She received an MD from Carol Davilla Medical School and a PhD in human genetics from the Romanian Academy of Medical Sciences. She also completed a doctoral fellowship at the University of Rene Descartes in Paris and a postdoctoral training at Baylor College of Medicine (BCM), Houston, Texas, USA, where she was also part of the faculty. She served as Vice-President of Research at VGX Pharmaceuticals (now Inovio) and VGX Animal Health. Her research activities have focused on molecular biology, gene therapy and vaccination. She is a global leader in the field of nucleic acid delivery for therapeutic and vaccination applications. Dr Draghia-Akli has demonstrated her commitment to research in the field of rare diseases via the framework programme FP7 and her unique leadership when launching the International Rare Disease Research Consortium (IRDiRC). The ambitious goal of this International Consortium is to develop 200 new therapies for rare diseases and the means to diagnose the most rare diseases by the year 2020.

Volunteer Award – Lesley Greene

Lesley Greene is a true pioneer of the rare disease movement in Europe. In 1980, upon the diagnosis of her firstborn daughter at age 15 months, Lesley and her husband Peter Greene established the charity Research Trust for Metabolic Diseases in Children (RTMDC), dedicated to this group of disorders. RTMDC is now known as CLIMB (Children Living with Inherited Metabolic Diseases). In 1995, Lesley was invited to join Abbey Myers (Founder of NORD) in Brussels, as a patient representative, to discuss the feasibility of developing an orphan drug legislation in Europe. After which RTMDC collaborated with other patient groups across Europe to support the adoption of the Regulation in 1999. Lesley is still active with respect to the Orphan regulation via her role as patients’ representative on the Committee for Orphan Medicinal Products, where she has served since 2009, and in her current position as Vice-Chair of the Committee since 2012. Lesley was elected as a Founder Director of EURORDIS in 1997 and from 2001 to 2003 she was EURORDIS’ President.
Dr Ségolène Aymé is a medical geneticist and Emeritus Research Director at the French National Institute of Health and Medical Research (INSERM). She developed Orphanet, the world’s leading reference portal for expert validated rare disease and orphan drug information. Orphanet, funded by the INSERM, the French Ministry of Health, the AFM Télélthon and the European Commission (DG Public Health and DG Research), is considered the most comprehensive, reliable, up-to-date resource available for rare disease and orphan drug information. Available in six languages and with partners in 38 countries, Orphanet provides open-access data for 6,000 rare diseases – including clinical descriptions, related genes, research projects, patient organisations, medicinal products under development or approved, laboratory diagnostic services, centres of expertise, emergency guidelines, and more. Dr Ségolène Aymé also serves as Chair of EUCERD, heads the Scientific Secretariat of the IRDiRC, is Chair of the Topical Advisory Group for Rare Diseases, is responsible for revising the International Classification of Diseases at the World Health Organisation, and is Editor-in-Chief of the Orphanet Journal of Rare Diseases (www.ojrd.com). Dr Ségolène Aymé has contributed to dozens of scientific articles, participated in numerous rare disease-related projects and committees, and plays a key role in bringing the scientific expertise in National and in EU-level policies.

Kay Parkinson is a unique leader who created an inspiring and exemplary patient organisation. After losing her two children because of late diagnosis of Alström disease, she studied law in order to better defend her children’s interests when she launched the patient organisation. One of the key achievements of Alström UK is the development of patient-led, NHS funded multi-disciplinary clinics for Alström Syndrome. Alström UK is a partner in the Euro-WABB project, an EU Rare Diseases Registry for Wolfram syndrome, Alström syndrome, Bardet-Biedl syndrome and other rare diabetes syndromes. The EURO-WABB Project is a collaboration of doctors, scientists and patient support groups from all over Europe. It is supported by the EU Directorate General for Health and Consumers (DG-SANCO) via its Executive Agency for Health and Consumers. The overall aim for this register is to be a key instrument to increase knowledge of these rare diseases, improve the lives of affected people through better management, and to develop clinical research. Alström UK is recognised by the EURORDIS Patient Organisation Award for its long-term commitment and outstanding achievements for Alström Syndrome patients.
Andrew Jack has been a journalist for the Financial Times since 1990. Since 2004, he has specialised in health and pharmaceuticals, based in He was one of a group of journalists to be awarded the “1993 British Press Awards Reporting Team of the Year” accolade for coverage of the Robert Maxwell affair. Mr Jack has written articles for medical journals including the British Medical Journal and the Lancet. A geography graduate from St Catharine’s College, Cambridge, Mr Jack was the Joseph Hodges Choate Memorial Fellow at Harvard University, Cambridge, Massachusetts; a New York City Government Urban Fellow; and a trustee of Pushkin House, a London-based centre for Russian culture. Mr Jack is being awarded the EURORDIS Media Award in recognition of his contribution to better the understanding of rare diseases and the issues surrounding these diseases through his articles written in the Financial Times during the past several years.

Since its inception in 1986, Celgene’s leadership in the research, discovery, development and marketing of treatments for rare cancers has significantly improved conditions for rare disease patients. Their steadfast and significant reinvestment in research and development place it in a position to make a life-changing difference for thousands more rare disease patients in the future. The Company’s commitment to innovation is reflected in the more than 200 clinical trials underway worldwide using compounds developed at Celgene. Celgene has created Celgene Patient Support® to assist patients worldwide in accessing products the Company has marketed in their respective countries. Celgene has a longstanding, supportive relationship with EURORDIS and other patients organisations in Europe and internationally. Most notably, the company supported the pilot and growth of RareConnect: the Online Patients Communities Project, which enables people affected by rare diseases to form communities across languages and geographic barriers.
Prosensa has achieved several Orphan Drug designations and developed an impressive clinical portfolio in the short time since its founding in 2002. With the Company’s commitment to “develop innovative, RNA based therapeutics to fill unmet medical needs for patients with genetic diseases,” Prosensa has the potential to make a life changing difference for people living with rare diseases. Prosensa currently has several compounds in development for treating Duchenne Muscular Dystrophy (DMD), including a development in collaboration with GlaxoSmithKline for the development and commercialization of RNA based therapeutics for DMD. Prosensa has established partnerships with the patient community through strategic partnerships with muscular dystrophy focused patient organisations, including EURORDIS Members Duchenne Parent Project, Aktion Beini & Co e.v., and the AFM (French Muscular Dystrophy Association).

Genzyme is a pioneer in researching, developing and marketing medicinal products for patients living with diseases. Now part of Sanofi, Genzyme, a Sanofi Company continues to offer hope to people living with genetic diseases, endocrine and cardiovascular diseases. Strategies to increase access to Genzyme products include free drug programs and humanitarian initiatives. Genzyme began this practice in 1999, establishing the Gaucher Initiative, a humanitarian partnership to provide the Company’s first product to Gaucher disease patients in developing countries. The Company is currently one of four co-funders of EURORDIS’ work in the EpiRare project, a three-year project designed to address the need for rare diseases registration throughout Europe. Genzyme is also a long-time sponsor of EURORDIS Membership Meetings and an Emerald Member of the EURORDIS Round Table of Companies.

As First Lady and now Former First Lady of Germany, Eva Luise Köhler has campaigned for the interests of people with chronic rare diseases and has taken over the patronage of the ACHSE. She is also the Chair of the Board of Trustees of the Eva Luise and Horst Köhler Foundation for people with rare diseases. Specifically, the Eva Luise and Horst Köhler Foundation supports research in the field of rare diseases. The foundation provides funding for basic and clinical research and awards 50,000 euros to a research team on an annual basis on the occasion of the official Rare Disease Day. The EURORDIS Lifetime Achievement Award is being presented to Mrs Köhler in recognition of her strong, lifelong dedication and commitment to addressing the needs of people living with a rare disease and for her contribution to the promotion of the rare disease cause in Germany.
Patient Organisation Award -  
**Association Française des Myopathies**

In recognition for its unmatched support for rare disease patients organisations throughout France and to EURORDIS, as well as outstanding success increasing awareness, raising funds and widely supporting research.

---

Volunteer Award -  
**Michele Lipucci Di Paola, PhD**

In recognition for his unshakable committed to improving conditions for people affected by rare diseases and particular dedication in Italy and on the European level.

---

Policy Maker Award – **Androulla Vassiliou, JD**

In recognition for her invaluable contribution to the rare disease community as Commissioner for Health and Consumer Policy from February 2008 to end of 2009. Her work to launch the Public Consultation, Rare Diseases: Europe’s Challenge, the consequent adoption of the Commission Communication on Rare Diseases, and the Council Recommendation on Rare Diseases, has laid the groundwork to improve conditions for rare disease patients in all Member States of the European Union.

---

European Rare Disease Achievement Award - **Kerstin Westermark, MD, PhD**

In recognition for her dedicated expertise and over a decade of support to those with rare diseases as the Swedish delegate and Chair of the Committee for Orphan Medicinal Products at the European Medicines’ Agency.
As an outstanding example of scientific research and European collaboration that has resulted in the successful development of the first gene therapy for rare diseases related to Severe Combined Immuno Deficiencies, which has set the stage for the extension of gene therapy to other genetic diseases with a high unmet medical need and for which there is currently no cure.

Scientific Award - Professor Alain Fisher and Professor Maria Grazia Roncarolo

In recognition of more than three decades of support raising awareness on rare diseases and covering rare disease issues from a patient perspective.

Media Award – BBC

Company Award – CSL Behring

In recognition of the Company’s long-standing commitment to rare disease patients, and most recently for its advances to benefit people living with primary immunodeficiency diseases and secondary immune-deficiencies.

Company Award – Shire

In recognition to Shire’s pioneering initiatives, particularly for patients with Hunter Syndrome and Gaucher Disease, and for the company’s on-going commitment to people living with rare diseases throughout Europe.

Company Award – Sigma Tau Pharmaceuticals, Inc

In recognition for being an early leader in developing medicines for rare diseases and for remaining an exemplary partner in the rare disease community.